Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The source of support to enable these meetings was provided in 2020 by AbbVie, Amgen, Eli Lilly & Co., Janssen, Novartis, Pfizer, UCB, Bristol Myers Squibb, Gilead, Boehringer-Ingelheim, and SunPharma. In addition, our Innovation Partner in 2020 was Nordic Bioscience. K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; A.B. Gottlieb, MD, PhD, Clinical Professor of Dermatology, Department of Dermatology, Icahn School of Medicine at Mount Sinai, and Co-chair, GRAPPA Publication Committee, New York, New York, USA; D. O’Sullivan, BE, GRAPPA Patient Research Partner, Our Lady’s Hospice & Care Services, Rheumatic & Musculoskeletal Disease Unit, Dublin, Ireland; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; L.V. McFarland, MS, PhD, Consultant, Public Health Reserves Corps, Seattle, Washington, USA. KCD reports the following conflicts of interest: grants/investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer-Ingelheim; speaker’s bureau for Novartis (nonpromotional only); consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, Boehringer-Ingelheim. There are no conflicts of interest for all other coauthors. Address correspondence to Dr. K. Callis Duffin, University of Utah, 4A330 Dermatology, SOM, 30 North 1900 East, Salt Lake City, UT 84132, USA. Email: Kristina.callis{at}hsc.utah.edu.

As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The source of support to enable these meetings was provided in 2020 by AbbVie, Amgen, Eli Lilly & Co., Janssen, Novartis, Pfizer, UCB, Bristol Myers Squibb, Gilead, Boehringer-Ingelheim, and SunPharma. In addition, our Innovation Partner in 2020 was Nordic Bioscience. K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; A.B. Gottlieb, MD, PhD, Clinical Professor of Dermatology, Department of Dermatology, Icahn School of Medicine at Mount Sinai, and Co-chair, GRAPPA Publication Committee, New York, New York, USA; D. O’Sullivan, BE, GRAPPA Patient Research Partner, Our Lady’s Hospice & Care Services, Rheumatic & Musculoskeletal Disease Unit, Dublin, Ireland; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; L.V. McFarland, MS, PhD, Consultant, Public Health Reserves Corps, Seattle, Washington, USA. KCD reports the following conflicts of interest: grants/investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer-Ingelheim; speaker’s bureau for Novartis (nonpromotional only); consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, Boehringer-Ingelheim. There are no conflicts of interest for all other coauthors. Address correspondence to Dr. K. Callis Duffin, University of Utah, 4A330 Dermatology, SOM, 30 North 1900 East, Salt Lake City, UT 84132, USA. Email: Kristina.callis{at}hsc.utah.edu.

As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The source of support to enable these meetings was provided in 2020 by AbbVie, Amgen, Eli Lilly & Co., Janssen, Novartis, Pfizer, UCB, Bristol Myers Squibb, Gilead, Boehringer-Ingelheim, and SunPharma. In addition, our Innovation Partner in 2020 was Nordic Bioscience. K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; A.B. Gottlieb, MD, PhD, Clinical Professor of Dermatology, Department of Dermatology, Icahn School of Medicine at Mount Sinai, and Co-chair, GRAPPA Publication Committee, New York, New York, USA; D. O’Sullivan, BE, GRAPPA Patient Research Partner, Our Lady’s Hospice & Care Services, Rheumatic & Musculoskeletal Disease Unit, Dublin, Ireland; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; L.V. McFarland, MS, PhD, Consultant, Public Health Reserves Corps, Seattle, Washington, USA. KCD reports the following conflicts of interest: grants/investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer-Ingelheim; speaker’s bureau for Novartis (nonpromotional only); consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, Boehringer-Ingelheim. There are no conflicts of interest for all other coauthors. Address correspondence to Dr. K. Callis Duffin, University of Utah, 4A330 Dermatology, SOM, 30 North 1900 East, Salt Lake City, UT 84132, USA. Email: Kristina.callis{at}hsc.utah.edu.

As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The source of support to enable these meetings was provided in 2020 by AbbVie, Amgen, Eli Lilly & Co., Janssen, Novartis, Pfizer, UCB, Bristol Myers Squibb, Gilead, Boehringer-Ingelheim, and SunPharma. In addition, our Innovation Partner in 2020 was Nordic Bioscience. K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; A.B. Gottlieb, MD, PhD, Clinical Professor of Dermatology, Department of Dermatology, Icahn School of Medicine at Mount Sinai, and Co-chair, GRAPPA Publication Committee, New York, New York, USA; D. O’Sullivan, BE, GRAPPA Patient Research Partner, Our Lady’s Hospice & Care Services, Rheumatic & Musculoskeletal Disease Unit, Dublin, Ireland; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; L.V. McFarland, MS, PhD, Consultant, Public Health Reserves Corps, Seattle, Washington, USA. KCD reports the following conflicts of interest: grants/investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer-Ingelheim; speaker’s bureau for Novartis (nonpromotional only); consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, Boehringer-Ingelheim. There are no conflicts of interest for all other coauthors. Address correspondence to Dr. K. Callis Duffin, University of Utah, 4A330 Dermatology, SOM, 30 North 1900 East, Salt Lake City, UT 84132, USA. Email: Kristina.callis{at}hsc.utah.edu.

As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The source of support to enable these meetings was provided in 2020 by AbbVie, Amgen, Eli Lilly & Co., Janssen, Novartis, Pfizer, UCB, Bristol Myers Squibb, Gilead, Boehringer-Ingelheim, and SunPharma. In addition, our Innovation Partner in 2020 was Nordic Bioscience. K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; A.B. Gottlieb, MD, PhD, Clinical Professor of Dermatology, Department of Dermatology, Icahn School of Medicine at Mount Sinai, and Co-chair, GRAPPA Publication Committee, New York, New York, USA; D. O’Sullivan, BE, GRAPPA Patient Research Partner, Our Lady’s Hospice & Care Services, Rheumatic & Musculoskeletal Disease Unit, Dublin, Ireland; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; L.V. McFarland, MS, PhD, Consultant, Public Health Reserves Corps, Seattle, Washington, USA. KCD reports the following conflicts of interest: grants/investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer-Ingelheim; speaker’s bureau for Novartis (nonpromotional only); consultant/advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, Boehringer-Ingelheim. There are no conflicts of interest for all other coauthors. Address correspondence to Dr. K. Callis Duffin, University of Utah, 4A330 Dermatology, SOM, 30 North 1900 East, Salt Lake City, UT 84132, USA. Email: Kristina.callis{at}hsc.utah.edu.